Results from the PERSEUS study led to FDA approval of Darzalex Faspro for patients with newly diagnosed multiple myeloma who are candidates for autologous stem cell transplant.
FDA Approves Johnson & Johnson’s Darzalex Faspro in Combination with Bortezomib, Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed Multiple Myeloma
Leave a comment
